Shadbash Piruz, Hosseini Seyed Masoud, Abyar Sahel, Shoraka Shahrzad, Ghaemi Amir, Naderi Nosratollah, Mohebbi Seyed Reza
Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Microbiology and Microbial Biotechnology, Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran.
Gastroenterol Hepatol Bed Bench. 2025;18(1):53-69. doi: 10.22037/ghfbb.v18i1.3066.
Pancreatic cancer (PC) remains one of the most formidable malignancies, with survival rates showing minimal improvement over the years despite progress in chemotherapy, targeted treatments, and radiation therapy. The development of targeted agents and chemotherapy for cancer treatment has only moderately influenced clinical results and has not significantly altered 5-year survival rates. However, with the rapid discovery of the genetic and molecular functions underlying PC, new opportunities for targeted therapies are emerging. One promising approach is oncolytic viral therapy, which has shown potential as a targeted agent for the treatment of pancreatic cancer. Based on the available evidence, oncolytic viral therapy appears to be a viable treatment option for pancreatic cancer. In the present narrative review, we explore oncolytic viruses in detail, and their potential applications in cancer therapy as a future alternative treatment are investigated.
胰腺癌（PC）仍然是最具威胁性的恶性肿瘤之一，尽管在化疗、靶向治疗和放射治疗方面取得了进展，但多年来生存率的改善微乎其微。用于癌症治疗的靶向药物和化疗的发展仅对临床结果产生了适度影响，并未显著改变5年生存率。然而，随着胰腺癌潜在的基因和分子功能的迅速发现，靶向治疗的新机会正在出现。一种有前景的方法是溶瘤病毒疗法，它已显示出作为治疗胰腺癌的靶向药物的潜力。基于现有证据，溶瘤病毒疗法似乎是胰腺癌的一种可行治疗选择。在本叙述性综述中，我们详细探讨了溶瘤病毒，并研究了它们作为未来替代治疗在癌症治疗中的潜在应用。
